Publication date: Apr 15, 2025
Adjuvant BRAF/MEK inhibitors (BRAF/MEK) and anti-PD-1 therapy have become the standard care in resected stage III/IV melanoma. A head-to-head clinical trial comparison is lacking. All stage III BRAF-mutant melanoma patients who received adjuvant BRAF/MEK or anti-PD-1 (2018-2022) were included from the Dutch Melanoma Treatment Registry. Propensity score matching (PSM) was used to compare 1- and 2-year recurrence-free survival (RFS), distant metastasis-free survival (DMFS), and overall survival (OS), and toxicity rates. Among 952 patients (226 BRAF/MEK and 726 anti-PD-1), BRAF/MEK-treated patients had lower disease stages (16.4% versus 9.9% stage IIIA; p
| Concepts | Keywords |
|---|---|
| Dutch | Adjuvant |
| Melanoma | Anti |
| Mutant | Braf |
| Stage | Clinical |
| Free | |
| Head | |
| Iii | |
| Mek | |
| Melanoma | |
| Mutant | |
| Pd | |
| Propensity | |
| Score | |
| Stage | |
| Survival |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | recurrence |
| disease | MESH | metastasis |
Original Article
(Visited 1 times, 1 visits today)